Last reviewed · How we verify
NCT06744179
Post TB Sequelae Study
trial testing echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire in Tuberculosis, Pulmonary in 600 participants. Enrolling by invitation.
7 June 2027
Quick facts
| Lead sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 7 July 2024 |
| Primary completion | 7 June 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire
Conditions studied
- Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh — full company profile →
Who can join
6 Months and older, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this prospective cohort study is to learn about the long-term health effects of tuberculosis (TB) in children, adolescents, and adults who have completed standard TB treatment in Bangladesh. The study aims to track the evolution of pulmonary and cardiac sequelae within the first two years after TB treatment completion. The main question it aims to answer is: Does completing TB treatment result in long-term pulmonary or cardiac health issues (post-TB lung disease, PTLD) in patients compared to those without TB? Additionally, how does this impact children\'s growth, radiological patterns, and overall quality of life? Participants who have completed anti-TB treatment for the first episode of pulmonary TB and non-TB participants (age- and sex-matched controls) will be followed for two years. The study will take place at multiple sites in Dhaka, including icddr,b Tuberculosis Screening \& Treatment Centers (TBSTC) and Dhaka Shishu Hospital. TB patients and controls will be recruited from Dhaka and surrounding areas. Over a two-year period, participants will be followed at five key points: within 5-7 days of treatment completion (T0), at 6 months (T1), 12 months (T2), 18 months (T3), and 24 months (T4). Data collection will involve comprehensive clinical evaluations, pulmonary and cardiovascular examinations, laboratory tests, and diagnostic imaging such as chest X-rays, ECGs, and pulmonary function tests. The study will address several key outcomes, including: The prevalence and incidence of post-TB lung disease and cardiac sequelae Weight gain and growth in children post-treatment Radiological and ECG patterns post-treatment Mental health and quality of life following TB recovery Associations between demographic, social, and lifestyle factors and post-TB sequelae Through this observational study, researchers hope to contribute valuable insights into the long-term health challenges faced by TB survivors, particularly among children, for whom such data is currently lacking.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06744179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis, Pulmonary
Currently open trials in the same condition.
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
- NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
- NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
- NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting
Other International Centre for Diarrhoeal Disease Research, Bangladesh trials
Trials by the same sponsor.
- NCT07537686 — Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunc · Phase 2 · not yet recruiting
- NCT07345208 — Safety and Immunogenicity of ID vs IM Rabies Vaccine · Phase 2, PHASE3 · not yet recruiting
- NCT07045493 — Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh · Phase 2 · enrolling by invitation
- NCT06757283 — ZyVac-TCV Bangladesh Study · Phase 3 · not yet recruiting
- NCT06815835 — Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06744179 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Centre for Diarrhoeal Disease Research, Bangladesh
- Last refreshed: 20 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06744179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing